Literature DB >> 8101872

Amplification of c-myc oncogene and absence of c-Ha-ras point mutation in human bone sarcoma.

C Barrios1, J S Castresana, J Ruiz, A Kreicbergs.   

Abstract

The genomic organization of four oncogenes, c-myc, c-myb, c-Ha-ras, and v-fms, was analyzed in 21 patients with malignant bone tumors. Amplification of the c-myc proto-oncogene without rearrangement was the sole abnormality detected in four tumors: two chondrosarcomas, one osteosarcoma, and one lymphoma of bone. DNA hybridizations with c-myb, c-Ha-ras, and v-fms probes disclosed no structural gene abnormalities. Point mutations at the 12th codon of the c-Ha-ras gene were investigated with the polymerase chain reaction technique; no alterations were detected. The observed amplification of the c-myc there was not related to histologic type, grade, surgical stage, or ploidy level of the tumors. The results indicated that c-myc amplification, presumed to be involved in the development of malignancy in a variety of solid tumors, is encountered sporadically in malignant bone tumors; however, this occurs without relation to common histopathologic features. The clinical significance of oncogene amplification in bone sarcoma remains to be established.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8101872     DOI: 10.1002/jor.1100110410

Source DB:  PubMed          Journal:  J Orthop Res        ISSN: 0736-0266            Impact factor:   3.494


  10 in total

1.  Malignant fibrous histiocytomas and H-ras-1 oncogene point mutations.

Authors:  P Rieske; J Bartkowiak; A Szadowska; M Debiec-Rychter
Journal:  Mol Pathol       Date:  1999-04

2.  Molecular basis of differentiation therapy for soft tissue sarcomas.

Authors:  Gaurav Luther; Richard Rames; Eric R Wagner; Gaohui Zhu; Qing Luo; Yang Bi; Stephanie H Kim; Jian-Li Gao; Enyi Huang; Ke Yang; Linyuan Wang; Xing Liu; Mi Li; Ning Hu; Yuxi Su; Xiaoji Luo; Liang Chen; Jinyong Luo; Rex C Haydon; Hue H Luu; Lan Zhou; Tong-Chuan He
Journal:  Trends Cancer Res       Date:  2010

Review 3.  New advances in the molecular biology of musculoskeletal neoplasms.

Authors:  J A Morcuende; J A Buckwalter
Journal:  Iowa Orthop J       Date:  1997

Review 4.  Osteosarcoma development and stem cell differentiation.

Authors:  Ni Tang; Wen-Xin Song; Jinyong Luo; Rex C Haydon; Tong-Chuan He
Journal:  Clin Orthop Relat Res       Date:  2008-06-18       Impact factor: 4.176

5.  MMP13, Birc2 (cIAP1), and Birc3 (cIAP2), amplified on chromosome 9, collaborate with p53 deficiency in mouse osteosarcoma progression.

Authors:  Ou Ma; Wei-Wen Cai; Lars Zender; Tajhal Dayaram; Jianhe Shen; Alan J Herron; Scott W Lowe; Tsz-Kwong Man; Ching C Lau; Lawrence A Donehower
Journal:  Cancer Res       Date:  2009-03-10       Impact factor: 12.701

6.  The Current and Future Therapies for Human Osteosarcoma.

Authors:  Joseph D Lamplot; Sahitya Denduluri; Jiaqiang Qin; Ruidong Li; Xing Liu; Hongyu Zhang; Xiang Chen; Ning Wang; Abdullah Pratt; Wei Shui; Xiaoji Luo; Guoxin Nan; Zhong-Liang Deng; Jinyong Luo; Rex C Haydon; Tong-Chuan He; Hue H Luu
Journal:  Curr Cancer Ther Rev       Date:  2013-02

7.  Defective osteogenic differentiation in the development of osteosarcoma.

Authors:  Eric R Wagner; Gaurav Luther; Gaohui Zhu; Qing Luo; Qiong Shi; Stephanie H Kim; Jian-Li Gao; Enyi Huang; Yanhong Gao; Ke Yang; Linyuan Wang; Chad Teven; Xiaoji Luo; Xing Liu; Mi Li; Ning Hu; Yuxi Su; Yang Bi; Bai-Cheng He; Ni Tang; Jinyong Luo; Liang Chen; Guowei Zuo; Richard Rames; Rex C Haydon; Hue H Luu; Tong-Chuan He
Journal:  Sarcoma       Date:  2011-02-22

8.  High VEGF with rapid growth and early metastasis in a mouse osteosarcoma model.

Authors:  Shang-You Yang; Haiying Yu; Jeffrey E Krygier; Paul H Wooley; Michael P Mott
Journal:  Sarcoma       Date:  2007

9.  Inhibition of malignant phenotypes of human osteosarcoma cells by a gene silencer, a pyrrole-imidazole polyamide, which targets an E-box motif.

Authors:  Masashi Taniguchi; Kyoko Fujiwara; Yuji Nakai; Toshinori Ozaki; Nobuko Koshikawa; Kojima Toshio; Motoaki Kataba; Asako Oguni; Hiroyuki Matsuda; Yukihiro Yoshida; Yasuaki Tokuhashi; Noboru Fukuda; Takahiro Ueno; Masayoshi Soma; Hiroki Nagase
Journal:  FEBS Open Bio       Date:  2014-03-13       Impact factor: 2.693

Review 10.  Molecular mechanisms underpinning sarcomas and implications for current and future therapy.

Authors:  Victoria Damerell; Michael S Pepper; Sharon Prince
Journal:  Signal Transduct Target Ther       Date:  2021-06-30
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.